Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
|Poll|March 1, 2019
Mini Quiz: Health Professionals and Barriers to Psychiatric Treatment
Author(s)Adam Bartlett Hill, MD
In a national epidemic of caregiver distress and suicide, what barriers still stand in the way of seeking mental health treatment for medical professionals?
Advertisement
In a national epidemic of caregiver distress and suicide, what barriers still stand in the way of seeking mental health treatment for medical professionals?
Advertisement
Related to this article
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Don't miss out on these CME articles! Test your knowledge here.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
3
How Best to Manage Treatment-Resistant Depression
4
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
5